You are here

bimagrumab

Regeneron, Lilly grapple with clinical endpoints as obesity space moves to improving weight loss

Fierce Biotech

Thu, 05/2/24 - 10:14 pm

Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis

Fierce Biotech

Fri, 07/14/23 - 10:10 am

Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity

MedCity News

Tue, 08/31/21 - 10:05 pm

clinical trials